Skip to main content
BioAdvance NewsPortfolio NewsRelmada Therapeutics

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

By August 9, 2022November 1st, 2024No Comments

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

See more here